{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-028109","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2026-08-17T11:55:11+00:00","discovered_at":"2026-08-17T12:00:06.948348+00:00","generated_at":"2026-08-17T12:03:01.130788+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuo Therapeutics Q2 2026 revenue up >150% YoY; operating loss narrows to $167K","bullets":["Q2 2026 total revenues ~$1.77M, up >150% YoY; H1 2026 revenues ~$3.07M, also up >150%.","Q2 product revenues up 38% sequentially; Aurix brand up >30% sequentially.","Q2 net operating loss ~$167K, improved ~$280K vs Q1 2026.","Amended loan: interim funding $675K, $325K remaining under $2M commitments; option to increase borrowings Sept 30, 2026.","Reimbursement fee milestone achieved under Smith+Nephew distribution agreement; payment expected this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-028109","json":"https://secwatch.observer/filing/0001437749-26-028109.json","markdown":"https://secwatch.observer/filing/0001437749-26-028109.md","text":"https://secwatch.observer/filing/0001437749-26-028109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/0001437749-26-028109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/aurx20260816c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-17T12:03:01.130788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}